About OMass Therapeutics
OMass Therapeutics is a company based in Oxford (United Kingdom) founded in 2016 by Carol Robinson. OMass Therapeutics has raised $166.24 million across 4 funding rounds from investors including Syncona, University of Oxford and Oxford University Innovation. The company has 36 employees as of September 30, 2021. OMass Therapeutics offers products and services including Biochemistry Services and Mass Spectrometry Solutions. OMass Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Aclaris Therapeutics, Neurocrine and ADMA Biologics, among others.
- Headquarter Oxford, United Kingdom
- Employees 36 as on 30 Sep, 2021
- Founders Carol Robinson
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Omass Therapeutics Limited
- Date of Incorporation 26 Feb, 2016
- Jurisdiction OXFORD, ENGLAND
-
Annual Revenue
$54.27 K (USD)-83as on Dec 31, 2019
-
Net Profit
-$12.52 M (USD)-47as on Dec 31, 2021
-
EBITDA
Not available
-
Total Equity Funding
$166.24 M (USD)
in 4 rounds
-
Latest Funding Round
$12.45 M (USD), Series B
May 15, 2023
-
Investors
Syncona
& 7 more
-
Employee Count
36
as on Sep 30, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OMass Therapeutics
OMass Therapeutics offers a comprehensive portfolio of products and services, including Biochemistry Services and Mass Spectrometry Solutions.
Provides tools for analyzing target interactions in ecosystems
Offers custom chemistry for drug discovery applications
People of OMass Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of OMass Therapeutics
OMass Therapeutics has successfully raised a total of $166.24M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $12.45 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OMass Therapeutics
OMass Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Syncona, University of Oxford and Oxford University Innovation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital co-investments are made in UK later-stage businesses.
|
Locked | Locked | Locked | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked | |
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Locked | Locked | Locked |
Investor details for OMass Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OMass Therapeutics
Investment portfolio details for OMass Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OMass Therapeutics
Detailed financials for OMass Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Omass Therapeutics Comparisons
Peer comparison for OMass Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OMass Therapeutics
OMass Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Aclaris Therapeutics, Neurocrine and ADMA Biologics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
Detailed competitors of OMass Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Omass Therapeutics
Complete news archive for OMass Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OMass Therapeutics
OMass Therapeutics was founded in 2016 and raised its 1st funding round 2 years after it was founded.
OMass Therapeutics is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
OMass Therapeutics is a funded company, having raised a total of $166.24M across 4 funding rounds to date.
As of Sep 30, 2021, the latest employee count at OMass Therapeutics is 36.
Annual revenue of OMass Therapeutics is $54.27K as on Dec 31, 2019.
OMass Therapeutics was founded in 2016 in Oxford, United Kingdom, within the biotechnology sector. Proprietary technologies based on mass spectrometry are utilized to examine protein assemblies, enabling detection of drug leads that bind to target complexes via non-covalent interactions and modulate complex formation for therapeutic effects. The pipeline encompasses MC2 for rare endocrine disorders, GPR65 for inflammatory bowel disease, Gasdermin D inhibitors for immunology, and KCC2 for epilepsy.
OMass Therapeutics's top competitors include Jazz Pharmaceuticals, ADMA Biologics and PTC Therapeutics.
OMass Therapeutics offers Biochemistry Services and Mass Spectrometry Solutions.
OMass Therapeutics has 8 investors. Key investors include Syncona, University of Oxford, Oxford University Innovation, British Patient Capital, and Google Ventures.